Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 15, 2010

MP Biomedicals Picks Up New Zealand-Based Protein Biologics Firm ICPbio

  • MP Biomedicals is acquiring New Zealand-based protein biologics manufacturing company ICPbio International. MP Biomedicals claims the acquisition means it will be able to add serum protein products for research, biopharmaceutical, and diagnostic applications to its existing lines of life science, fine chemical, and diagnostic products and services.

    ICPbio uses what it calls state-of-the-art chromatographic extraction to isolate high purity intact proteins. The firm’s current product portfolio includes bovine-derived thrombin, transferrin, albumin, and IgG.

    “We feel that this world-class protein-separation platform provides the manufacturing organization resources needed for MP Biomedicals to more fully serve customer demands for quality, low-risk serum protein materials collected and produced in the pristine environment of New Zealand,” comments Milan Panic, chairman and CEO at MP Biomedicals.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »